Sab BiotherapeuticsSABS
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 25 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings, up 3 from Q2 2024. 6 opened new positions and 2 sold out. The largest holders were BVF Inc. ($2.5M), RTW Investments, LP ($1.7M) and Marshall Wace, LLP ($1.2M). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $405K |
| Exits | 2 | $19 |
All 13F filers, Q2 2024 → Q3 2024: 158,273 shares bought and 132,896 shares sold, net +25,377 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 25 holders
| BVF Inc. | 0.07% | No change | 917,826 | $2.5M |
| RTW Investments, LP | 0.02% | Reduce -17.2% | 635,276 | $1.7M |
| Marshall Wace, LLP | 0.00% | No change | 459,168 | $1.2M |
| Sessa Capital IM, L.P. | 0.05% | No change | 458,457 | $1.2M |
| Vanguard Group Inc. | 0.00% | No change | 276,336 | $746K |
| HB Wealth Management, LLC | 0.00% | New | 108,600 | $293K |
| Geode Capital Management, LLC | 0.00% | Add +13.7% | 67,542 | $182K |
| Millennium Management | 0.00% | Reduce -1.6% | 51,946 | $140K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $137K |
| First Manhattan Co. Llc. | 0.00% | No change | 24,577 | $66K |
| BlackRock, Inc. | 0.00% | — | 22,165 | $60K |
| First PREMIER Bank | 0.01% | No change | 19,386 | $52K |
| NorthCoast Asset Management LLC | 0.00% | New | 19,201 | $52K |
| Kestra Advisory Services, LLC | 0.00% | New | 11,930 | $32K |
| Citadel Advisors | 0.00% | New | 10,305 | $28K |
| Osaic Holdings, Inc. | 0.00% | No change | 4,534 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -12.9% | 2,085 | $6K |
| Morgan Stanley | 0.00% | No change | 699 | $2K |
| Princeton Global Asset Management LLC | 0.00% | No change | 500 | $1K |
| GS Investments, Inc. | 0.00% | No change | 200 | $540 |
| JPMorgan Chase & Co. | 0.00% | No change | 106 | $286 |
| Sachetta, LLC | 0.00% | New | 100 | $270 |
| Bank of America Corp. | 0.00% | Reduce -41.2% | 97 | $262 |
| Harbour Investments, Inc. | 0.00% | No change | 50 | $135 |
| Barclays PLC | 0.00% | New | 10 | $27 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.